Last reviewed · How we verify

Effect of drug on inflammatory biomarkers

National Institute of Allergy and Infectious Diseases (NIAID) · Phase 1 active Small molecule Quality 10/100

Effect of drug on inflammatory biomarkers is a Small molecule drug developed by National Institute of Allergy and Infectious Diseases (NIAID). It is currently in Phase 1 development.

At a glance

Generic nameEffect of drug on inflammatory biomarkers
SponsorNational Institute of Allergy and Infectious Diseases (NIAID)
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Effect of drug on inflammatory biomarkers

What is Effect of drug on inflammatory biomarkers?

Effect of drug on inflammatory biomarkers is a Small molecule drug developed by National Institute of Allergy and Infectious Diseases (NIAID).

Who makes Effect of drug on inflammatory biomarkers?

Effect of drug on inflammatory biomarkers is developed by National Institute of Allergy and Infectious Diseases (NIAID) (see full National Institute of Allergy and Infectious Diseases (NIAID) pipeline at /company/national-institute-of-allergy-and-infectious-diseases-niaid).

What development phase is Effect of drug on inflammatory biomarkers in?

Effect of drug on inflammatory biomarkers is in Phase 1.

What are the side effects of Effect of drug on inflammatory biomarkers?

Common side effects of Effect of drug on inflammatory biomarkers include Alanine aminotransferase increased, Blood phosphorus decreased, Blood sodium decreased, Nausea, Vomiting, Aspartate aminotransferase increased.

Related